Thermo Fisher Scientific
Quarterly and annual revenue from company filings.
Business lines and operating measures.
Reported quarterly Chromatography and mass spectrometry · Operating Segments revenue. Quarterly figures · USD
| Period ended | USD | Report |
|---|---|---|
| Jun 27, 2026From Mar 29, 2026 | 821,000,000 | Filed Jul 31, 2026 |
| Mar 28, 2026From Jan 1, 2026 | 798,000,000 | Filed May 1, 2026 |
| Jun 28, 2025From Mar 30, 2025 | 784,000,000 | Filed Jul 31, 2026 |
| Mar 29, 2025From Jan 1, 2025 | 773,000,000 | Filed May 1, 2026 |
Reported quarterly Electron microscopy · Operating Segments revenue. Quarterly figures · USD
| Period ended | USD | Report |
|---|---|---|
| Jun 27, 2026From Mar 29, 2026 | 707,000,000 | Filed Jul 31, 2026 |
| Mar 28, 2026From Jan 1, 2026 | 633,000,000 | Filed May 1, 2026 |
| Jun 28, 2025From Mar 30, 2025 | 652,000,000 | Filed Jul 31, 2026 |
| Mar 29, 2025From Jan 1, 2025 | 659,000,000 | Filed May 1, 2026 |
Reported quarterly Research and safety market channel · Operating Segments revenue. Quarterly figures · USD
| Period ended | USD | Report |
|---|---|---|
| Jun 27, 2026From Mar 29, 2026 | 2,036,000,000 | Filed Jul 31, 2026 |
| Mar 28, 2026From Jan 1, 2026 | 1,827,000,000 | Filed May 1, 2026 |
| Jun 28, 2025From Mar 30, 2025 | 1,883,000,000 | Filed Jul 31, 2026 |
| Mar 29, 2025From Jan 1, 2025 | 1,727,000,000 | Filed May 1, 2026 |
Independent series; they may overlap and do not form an additive breakdown.
Our bioproduction business provides solutions for both the production of biologics and industrial manufacturing, and offers a comprehensive portfolio of premium solutions and services focused on upstream cell culture, downstream purification, analytics for detection, quantitation, filtration and separation of process/product impurities, and a suite of single-use solutions spanning the biologics workflow.
Highlights include the Thermo Scientific™ Orbitrap™ Tribrid™ Apex Mass Spectrometer, which enables researchers to study complex biology across multiomics, structural biology, biopharma characterization and small-molecule analysis on a single system, and the Thermo Scientific™ Orbitrap™ Excedion™ Mass Spectrometer, which enables scientists to identify hard-to-detect molecules in drug development, reducing risk and accelerating time to market.
| Fiscal quarter | Ended | Total revenueUSD millions |
|---|---|---|
| FY 2026 Q2 | Jun 27, 2026 | 11,994, +9.0% versus FY 2026 Q1 |
| FY 2026 Q1 | Mar 28, 2026 | 11,005, −9.9% versus FY 2025 Q4 |
| FY 2025 Q4 | Dec 31, 2025 | 12,215, +9.8% versus FY 2025 Q3 |
| FY 2025 Q3 | Sep 27, 2025 | 11,122, +2.5% versus FY 2025 Q2 |
| FY 2025 Q2 | Jun 28, 2025 | 10,855, +4.7% versus FY 2025 Q1 |
| FY 2025 Q1 | Mar 29, 2025 | 10,364, −9.0% versus FY 2024 Q4 |
| FY 2024 Q4 | Dec 31, 2024 | 11,395, +7.5% versus FY 2024 Q3 |
| FY 2024 Q3 | Sep 28, 2024 | 10,598, +0.5% versus FY 2024 Q2 |
| FY 2024 Q2 | Jun 29, 2024 | 10,541, +1.9% versus FY 2024 Q1 |
| FY 2024 Q1 | Mar 30, 2024 | 10,345, −5.0% versus FY 2023 Q4 |
| FY 2023 Q4 | Dec 31, 2023 | 10,886, +3.0% versus FY 2023 Q3 |
| FY 2023 Q3 | Sep 30, 2023 | 10,574, −1.1% versus FY 2023 Q2 |
| FY 2023 Q2 | Jul 1, 2023 | 10,687, −0.2% versus FY 2023 Q1 |
| FY 2023 Q1 | Apr 1, 2023 | 10,710, −6.5% versus FY 2022 Q4 |
| FY 2022 Q4 | Dec 31, 2022 | 11,450, +7.2% versus FY 2022 Q3 |
| FY 2022 Q3 | Oct 1, 2022 | 10,677, −2.7% versus FY 2022 Q2 |
| FY 2022 Q2 | Jul 2, 2022 | 10,970, −7.2% versus FY 2022 Q1 |
| FY 2022 Q1 | Apr 2, 2022 | 11,818, +10.4% versus FY 2021 Q4 |
| FY 2021 Q4 | Dec 31, 2021 | 10,702, +14.7% versus FY 2021 Q3 |
| FY 2021 Q3 | Oct 2, 2021 | 9,330, +0.6% versus FY 2021 Q2 |
| FY 2021 Q2 | Jul 3, 2021 | 9,273, −6.4% versus FY 2021 Q1 |
| FY 2021 Q1 | Apr 3, 2021 | 9,906, −6.1% versus FY 2020 Q4 |
| FY 2020 Q4 | Dec 31, 2020 | 10,550, +23.8% versus FY 2020 Q3 |
| FY 2020 Q3 | Sep 26, 2020 | 8,521, +23.2% versus FY 2020 Q2 |
| FY 2020 Q2 | Jun 27, 2020 | 6,917, +11.0% versus FY 2020 Q1 |
| FY 2020 Q1 | Mar 28, 2020 | 6,230, −8.8% versus FY 2019 Q4 |
| FY 2019 Q4 | Dec 31, 2019 | 6,829, +8.9% versus FY 2019 Q3 |
| FY 2019 Q3 | Sep 28, 2019 | 6,272, −0.7% versus FY 2019 Q2 |
| FY 2019 Q2 | Jun 29, 2019 | 6,316, +3.1% versus FY 2019 Q1 |
| FY 2019 Q1 | Mar 30, 2019 | 6,125, −5.9% versus FY 2018 Q4 |
| FY 2018 Q4 | Dec 31, 2018 | 6,507, +9.9% versus FY 2018 Q3 |
| FY 2018 Q3 | Sep 29, 2018 | 5,920, −2.6% versus FY 2018 Q2 |
| FY 2018 Q2 | Jun 30, 2018 | 6,078, +3.8% versus FY 2018 Q1 |
| FY 2018 Q1 | Mar 31, 2018 | 5,853, −3.2% versus FY 2017 Q4 |
| FY 2017 Q4 | Dec 31, 2017 | 6,047, +18.2% versus FY 2017 Q3 |
| FY 2017 Q3 | Sep 30, 2017 | 5,116.2, +2.5% versus FY 2017 Q2 |
| FY 2017 Q2 | Jul 1, 2017 | 4,990, +4.7% versus FY 2017 Q1 |
| FY 2017 Q1 | Apr 1, 2017 | 4,765, −3.8% versus FY 2016 Q4 |
| FY 2016 Q4 | Dec 31, 2016 | 4,953.2, +10.3% versus FY 2016 Q3 |
| FY 2016 Q3 | Oct 1, 2016 | 4,490.9, −1.0% versus FY 2016 Q2 |
| FY 2016 Q2 | Jul 2, 2016 | 4,535.2, +5.6% versus FY 2016 Q1 |
| FY 2016 Q1 | Apr 2, 2016 | 4,294.8, −7.7% versus FY 2015 Q4 |
| FY 2015 Q4 | Dec 31, 2015 | 4,652.5, +12.8% versus FY 2015 Q3 |
| FY 2015 Q3 | Sep 26, 2015 | 4,123.2, −3.5% versus FY 2015 Q2 |
| FY 2015 Q2 | Jun 27, 2015 | 4,270.9, +9.0% versus FY 2015 Q1 |
| FY 2015 Q1 | Mar 28, 2015 | 3,918.8, −12.8% versus FY 2014 Q4 |
| FY 2014 Q4 | Dec 31, 2014 | 4,492.8, +7.7% versus FY 2014 Q3 |
| FY 2014 Q3 | Sep 27, 2014 | 4,171.4, −3.5% versus FY 2014 Q2 |
| FY 2014 Q2 | Jun 28, 2014 | 4,321.9, +10.7% versus FY 2014 Q1 |
| FY 2014 Q1 | Mar 29, 2014 | 3,903.5, +12.6% versus FY 2013 Q4 |
| FY 2013 Q4 | Dec 31, 2013 | 3,466.9, +8.6% versus FY 2013 Q3 |
| FY 2013 Q3 | Sep 28, 2013 | 3,191.8, −1.5% versus FY 2013 Q2 |
| FY 2013 Q2 | Jun 29, 2013 | 3,240.1, +1.5% versus FY 2013 Q1 |
| FY 2013 Q1 | Mar 30, 2013 | 3,191.5, −2.1% versus FY 2012 Q4 |
| FY 2012 Q4 | Dec 31, 2012 | 3,259.3, +5.6% versus FY 2012 Q3 |
| FY 2012 Q3 | Sep 29, 2012 | 3,085.7, −0.7% versus FY 2012 Q2 |
| FY 2012 Q2 | Jun 30, 2012 | 3,108.1, +0.3% versus FY 2012 Q1 |
| FY 2012 Q1 | Mar 31, 2012 | 3,100.3, −1.1% versus FY 2011 Q4 |
| FY 2011 Q4 | Dec 31, 2011 | 3,133.6, +5.4% versus FY 2011 Q3 |
| FY 2011 Q3 | Oct 1, 2011 | 2,973.5, +2.6% versus FY 2011 Q2 |
| FY 2011 Q2 | Jul 2, 2011 | 2,897.4, +6.5% versus FY 2011 Q1 |
| FY 2011 Q1 | Apr 2, 2011 | 2,721.4, −2.1% versus FY 2010 Q4 |
| FY 2010 Q4 | Dec 31, 2010 | 2,781.1, +3.6% versus FY 2010 Q3 |
| FY 2010 Q3 | Oct 2, 2010 | 2,683.5, +1.3% versus FY 2010 Q2 |
| FY 2010 Q2 | Jul 3, 2010 | 2,649, −1.0% versus FY 2010 Q1 |
| FY 2010 Q1 | Apr 3, 2010 | 2,675.1, −5.8% versus FY 2009 Q4 |
| FY 2009 Q4 | Dec 31, 2009 | 2,839.4, +12.2% versus FY 2009 Q3 |
| FY 2009 Q3 | Sep 26, 2009 | 2,531.1, +1.9% versus FY 2009 Q2 |
| FY 2009 Q2 | Jun 27, 2009 | 2,484.1, Change unavailable versus FY 2009 Q1 |
Figures from official company filings and financial reports, in the reported currency. FY identifies the fiscal year; the end date identifies the calendar period. Last checked Oct 19, 2026.
Annual values come from annual filings. Historical quarters retain their reporting basis; rounding and reclassifications can make their sum differ from the annual figure. YTD sums the available fiscal quarters and compares the same quarters of the previous fiscal year.
Missing values are shown as unavailable. Fourth quarters use reported values where available, otherwise the annual amount less the matching nine-month amount.